Stallergenes in brief

For 50 years, Stallergenes is specialized in the treatment of severe respiratory allergies, such as severe rhino conjunctivitis and rhinitis as well as allergic asthma. 

With a total workforce of more than 1000 employees, Stallergenes distributes its products in more than 50 countries, notably through 17 subsidiaries.

A true research-based company, Stallergenes annually devotes close to 20% of its turnover to research and development and is actively involved in the pharmaceutical and clinical development program Stalair^®: the sublingual allergen immunotherapy tablets that form a new therapeutic class covering 80% of respiratory allergies.